Baylor Scott and White Research Institute, Charles A. Sammons Cancer Center

Dallas, Texas 75246

0 studies enrolling now · 2 studies all time

What they study most

AML, Refractory Multiple Myeloma

Studies at this site

• Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients — Completed
• A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma — Stopped early